articleTop 1% cited

Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

Journal of Clinical Oncology · 2000 · Vol. 18(10) · pp. 2095–2103

Frances A. Shepherd✉(Regional Cancer Center)Janet Dancey(Regional Cancer Center)Rodryg Ramlau(Regional Cancer Center)K. Mattson(Regional Cancer Center)Richard J. Gralla(Regional Cancer Center)Mark Allen O’Rourke(Regional Cancer Center)Nathan Levitan(Regional Cancer Center)Laurent Gressot(Regional Cancer Center)Mark Vincent(Regional Cancer Center)Ronald L. Burkes(Regional Cancer Center)Susan Coughlin(Regional Cancer Center)Yong Kim(Regional Cancer Center)J. Bérille(Regional Cancer Center)

View via DOI Publisher page

Abstract

Treatment with docetaxel is associated with significant prolongation of survival, and at a dose of 75 mg/m(2), the benefits of docetaxel therapy outweigh the risks.

Lung Cancer Diagnosis and Treatment Lung Cancer Treatments and Mutations Lung Cancer Research StudiesMedicineDocetaxelChemotherapyOncologyLung cancerInternal medicineRandomized controlled trialCancer

MeSH terms

DocetaxelAdultAgedAntineoplastic AgentsAntineoplastic Agents, PhytogenicCarcinoma, Non-Small-Cell LungCisplatinFemaleHumansLung NeoplasmsMaleMiddle AgedPalliative CareProspective StudiesQuality of Life

Citations

2,183

FWCI

83.31

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy